Value in Oncology
The presidential keynote address at ASCO 2015 was presented by Michael E. Porter, PhD, MBA, Bishop William Lawrence University Professor, Harvard Business School, Boston, who started the value discussions a decade ago.
At the special session on value during ASCO 2015, Jennifer Malin, MD, PhD, presented the payer perspective on value in cancer care
Recent breakthroughs in cancer treatments have come with an enormous price, forcing patients to make difficult trade-offs between very high out-of-pocket costs and expensive treatment, with measurable but often modest health benefits.
According to one breast cancer advocate, when patients are asked to define “value” in the context of their cancer treatment, cost is not the first thing that comes to mind.
Oncologists should become value-based providers by eliminating unnecessary tests, prescribing cheaper alternatives when therapeutic equivalents exist, and keep calling for payment reform, said Ezekiel J. Emanuel, MD, PhD, Chair of the Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, at ASCO 2014. These measures will add value as a bridge to payment reform, which is the ultimate change that will bring value to cancer care, Dr Emanuel emphasized.
ASCO is starting to address the issue of value in cancer care, “moving the needle” away from cost alone, according to Lowell E. Schnipper, MD, the Berenson Professor in Medicine, Harvard Medical School, Boston, and Chair of the ASCO Task Force on Value in Cancer Care.
Two presentations at ASCO 2014 struck Jennifer Malin, MD, PhD, Medical Director of Oncology at WellPoint, Inc, as good examples of value in cancer care, but many other studies did not make the value-based list. Dr Malin described these studies at an ASCO Highlights of the Day session.
The need to design insurance coverage that promotes value in cancer care is no longer a matter of debate, but how to accomplish it remains a huge challenge, according to Lee N. Newcomer, MD, UnitedHealthcare Senior Vice President of Oncology, Women’s Health and Genetics, who discussed value in cancer care from the payer’s perspective at ASCO 2014.
The growing affiliation of community oncology practices with hospitals and other networks is an obstacle to achieving value in cancer care, according to Lee N. Newcomer, MD, UnitedHealthcare Senior Vice President of Oncology, Women’s Health and Genetics.
Page 3 of 3
Results 21 - 30 of 30
Results 21 - 30 of 30